

Tumor Necrosis Factor Antagonist Therapy and Lymphoma Development

Twenty-Six Cases Reported to the Food and Drug Administration

S. Lori Brown,¹ Mark H. Greene,² Sharon K. Gershon,¹ Evelyne T. Edwards,¹
and M. Miles Braun¹

Objective. Etanercept and infliximab are tumor necrosis factor (TNF) antagonists that have been recently approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). This study was undertaken to investigate the occurrence of lymphoproliferative disorders in patients treated with these agents.

Methods. Relevant data in the MedWatch post-market adverse event surveillance system run by the US Food and Drug Administration were reviewed.

Results. We identified 26 cases of lymphoproliferative disorders following treatment with etanercept (18 cases) or infliximab (8 cases). The majority of cases (81%) were non-Hodgkin's lymphomas. The interval between initiation of therapy with etanercept or infliximab and the development of lymphoma was very short (median 8 weeks). In 2 instances (1 infliximab, 1 etanercept), lymphoma regression was observed following discontinuation of anti-TNF treatment, in the absence of specific cytotoxic therapy directed toward the lymphoma.

Conclusion. Although data from a case series

such as this cannot establish a clear causal relationship between exposure to these medications and the risk of lymphoproliferative disease, the known predisposition of patients with RA and CD to lymphoma, the known excess of lymphoma in other immunosuppressed populations, and the known immunosuppressive effects of the anti-TNF drugs provide a biologic basis for concern and justification for the initiation of additional epidemiologic studies to formally evaluate this possible association.

In 1998 the Food and Drug Administration (FDA) approved 2 tumor necrosis factor (TNF) antagonists for human use. Etanercept is a dimeric fusion protein of the extracellular ligand binding portion of the human TNF receptor (p75), linked to the Fc portion of a human IgG molecule. It is indicated for the treatment of rheumatoid arthritis (RA) in patients whose disease has not responded to other disease-modifying antirheumatic drugs. Infliximab is a chimeric monoclonal antibody that binds specifically and directly to human TNF α and neutralizes its biologic activity. It is indicated for the treatment of moderate to severely active Crohn's disease (CD) and of RA.

Lymphoproliferative disorders, especially non-Hodgkin's lymphoma, occur at an increased rate in immunodeficient or immunosuppressed patients (1). Patients with RA are also at increased risk of lymphoproliferative disease, both non-Hodgkin's lymphoma and Hodgkin's disease (2–11). Some of this risk appears intrinsic to the natural history of untreated RA and has been attributed to the dysregulated immune function that is part of the pathophysiology of the disease (2–5,7,12). An excess risk of lymphoma has also been reported in patients with CD, although the risk does not

The opinions or assertions presented herein are the private views of the authors and are not to be construed as conveying either an official endorsement or criticism by the US Department of Health and Human Services, the Public Health Service, or the Food and Drug Administration.

¹S. Lori Brown, PhD (current address: Center for Devices and Radiological Health, FDA), Sharon K. Gershon, PharmD, Evelyne T. Edwards, PharmD, M. Miles Braun, MD: Center for Biologics Evaluation and Research, FDA, Rockville, Maryland; ²Mark H. Greene, MD: National Cancer Institute, Rockville, Maryland.

Address correspondence and reprint requests to M. Miles Braun, MD, Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM-210, Rockville, MD 20852-1448. E-mail: braunm@cber.fda.gov.

Submitted for publication May 9, 2002; accepted in revised form August 16, 2002.

Table 1. Lymphomas occurring in patients treated with etanercept*

Patient	Age/sex	Lymphoma cell type	Weeks from first etanercept dose to lymphoma diagnosis	Vital status	Immunosuppressive drugs			EBV associated with lymphoma
					MTX	Other	CTD	
1	69/F	Diffuse large B cell NHL	2	Alive	C	–	–	NR
2	84/F	Large cell NHL	8	Alive	C	–	–	SLE NR
3	66/F	Diffuse large B cell NHL (recurrent)	4	Dead	–	–	–	NR NR
4	45/F	Small T cell NHL	4	Dead	Unknown	CYC	DM	NR
5	67/F	Diffuse large B cell NHL	8	Alive	C	–	–	NR
6	61/F	Diffuse large cell NHL	8	Alive	C	–	–	NR
7	69/F	B cell NHL, n.o.s.	16	Alive	–	AZA	–	NR
8†	48/F	Follicular mixed small and large cell NHL	8	Alive	C	AZA	SS	NR
9	61/M	Mantle cell B cell NHL	8	Alive	C	Unknown	–	NR
10	76/F	NHL, n.o.s.	12	Alive	P	Unknown	NR	NR
11	50/F	NHL, n.o.s.	40	Alive	C	Unknown	NR	NR
12‡	73/M	Mantle cell B cell NHL	3	Alive	P	AZA, INF	NR	NR
13	60/M	B cell NHL	40	Alive	C	–	–	Negative
14	57/M	Large cell NHL	8	Alive	C	–	–	NR
15	75/F	Small lymphocytic B cell NHL	36	Alive	–	–	SS	NR
16	55/M	Diffuse large cell NHL (recurrent)	NR	Dead	–	–	–	NR
17§	44/M	Type B1 thymoma	12	Alive	P	–	–	NR
18	68/M	Hodgkin's disease, nodular sclerosing subtype	52	Alive	P	–	–	NR

* MTX = methotrexate; CTD = connective tissue disease (other than rheumatoid arthritis); EBV = Epstein-Barr virus; NHL = non-Hodgkin's lymphoma; C = concurrent with etanercept; NR = not reported; SLE = systemic lupus erythematosus; CYC = cyclophosphamide; DM = dermatomyositis; n.o.s. = not otherwise specified; AZA = azathioprine; SS = Sjögren's syndrome; P = prior to etanercept; INF = infliximab.

† Father reported to have died of non-Hodgkin's lymphoma at age 53.

‡ Patient received infliximab therapy for 2 years prior to being switched to etanercept. He developed lymphoma 3 weeks after beginning etanercept therapy, and is included in this table because he was taking etanercept at the time lymphoma developed.

§ Patient showed radiographic and histologic evidence of tumor shrinkage after etanercept was discontinued. Traditional antilymphoma chemotherapy was never administered.

appear to be as great as that seen in RA (13,14), and contradictory reports have been published (15). In some studies, the apparent excess of lymphoma in CD patients appears to be, at least in part, independent of exposure to immunosuppressive medications (16).

However, a proportion of the RA- or CD-associated lymphoproliferative disorders has also been attributed to the immunosuppressive effects of the medications used to treat these diseases, most notably azathioprine (AZA), cyclophosphamide, and methotrexate (MTX) for RA (17–22) and AZA for CD (15,23,24). Further support for the hypothesis that medication-related immunosuppression plays an etiologic role in these settings is the clinical observation that a fraction of the lymphomas regress when these treatments are discontinued, without specific antilymphoma chemotherapy having been instituted (25–28).

Another important feature of immunosuppression-associated lymphomas is the relationship between many of these malignancies and infection with the Epstein-Barr virus (EBV), a well-established cause of lymphoma in immunosuppressed patients, particularly in those who have undergone organ transplantation

(29,30). Some lymphoproliferative disorders observed in patients with RA have been shown to be associated with EBV (21,28).

In the present report, 26 cases of lymphoproliferative disease in patients receiving etanercept or infliximab therapy are described. The possible relationship between these lymphoproliferative neoplasms and concurrent therapy with TNF antagonists is explored.

METHODS

We examined MedWatch reports submitted to the Food and Drug Administration (FDA) for the biologic products etanercept and infliximab. MedWatch is the FDA's post-market adverse event surveillance system that receives and tabulates submitted reports of possible medication-related toxicities. All reports citing neoplasms, benign or malignant, were reviewed. Any report with a keyword of lymphoma or that mentioned lymphoma in the text was investigated further. The cases reported to MedWatch through December 2000 comprise the basis for the current summary.

Physicians, nonphysician health care practitioners, or others who submitted these reports were contacted first by phone, to alert them of our investigation. A letter was then sent to the adverse event reporter by both fax and mail,

requesting further information on the reported cancer, including 1) the interval between the initiation of etanercept or infliximab therapy and lymphoma diagnosis; 2) the site of cancer origin; 3) history of a connective tissue disorder other than RA; 4) previous or concurrent exposure to immunosuppressive agents; 5) evidence of lymphoma regression after etanercept or infliximab was stopped, but prior to antilymphoma therapy; 6) results of any laboratory studies performed to assess whether the patient's lymphoma might have been related to EBV infection; and 7) a copy of the lymphoma pathology report. Physicians were also asked to send representative surgical pathology specimens when available. If there was no response to the first letter, a second letter was sent requesting the information.

RESULTS

Etanercept-associated lymphoma. Eighteen cases of lymphoma occurring after the initiation of etanercept therapy were reported to the FDA between May 1999 and December 2000 (Table 1). Three patients were reported to be deceased. Two deaths occurred in patients in whom a previously diagnosed and treated non-Hodgkin's lymphoma recurred after the initiation of etanercept therapy (in both patients the lymphoma was in remission at the time etanercept was begun) and the third occurred in a patient with nodular sclerosing Hodgkin's disease. Lymphoma was diagnosed a median of 8 weeks (range 2–52 weeks) after the initiation of etanercept treatment.

The median age of the patients treated with etanercept was 64 years. The majority of patients were female (61%), and the most common indication for use of etanercept agent was RA (83%) (Table 2). Frequently, patients receiving etanercept were reported to be taking MTX concurrently (9 of 18) or to have a history of prior exposure to MTX (4 of 18), or other immunosuppressive drugs (4 of 18). Sixteen of the etanercept-associated lymphoproliferative disorders were non-Hodgkin's lymphoma, with Hodgkin's disease and thymoma represented by 1 case each. The histologic subtypes of non-Hodgkin's lymphoma in these cases (Table 1), as reported by the original diagnosing pathologist, were generally similar to those previously described in RA patients (7), with diffuse, large B cell lymphoma comprising the largest proportion.

The number of etanercept users in the US through January 2001 is estimated by the manufacturer to be 95,500. A crude approximation of the lymphoma rate among US residents exposed to etanercept would therefore be 18/95,500, or ~19 cases per 100,000 treated persons. This is almost certainly an underestimate, given

Table 2. Characteristics of the population of patients who developed lymphoma after treatment with etanercept or infliximab*

Characteristic	Etanercept (n = 18)	Infliximab (n = 8)
Age, years		
25–40	–	2 (25.0)
41–50	4 (22.2)	1 (12.5)
51–60	3 (16.7)	–
61–70	7 (38.9)	3 (37.5)
≥71	4 (22.2)	1 (12.5)
Not specified	–	1 (12.5)
Sex		
Female	11 (61.1)	2 (25.0)
Male	7 (38.9)	5 (62.5)
Not specified	–	1 (12.5)
Indication for TNF antagonist use		
Rheumatoid arthritis	15 (83.3)	3 (37.5)
Psoriatic arthritis	2 (11.1)	–
Crohn's disease	–	5 (62.5)
Not specified	1 (5.6)	–
No. of other medications taken concurrently		
1–3	8 (44.4)	3 (37.5)
4–7	3 (16.7)	3 (37.5)
≥8	4 (22.2)	–
Not specified	3 (16.7)	2 (25.0)
Past or concurrent MTX use	13 (72.2)	2 (25.0)
Past or concurrent use of any immunosuppressive drug (including MTX)	15 (83.3)	4 (50.0)
Weeks from first TNF antagonist dose to lymphoma diagnosis†		
0–8	10 (55.6)	4 (50.0)
9–16	3 (16.7)	–
17–24	–	1 (12.5)
≥25	4 (22.2)	2 (25.0)
Not specified	1 (5.6)	1 (12.5)
Died	3 (16.7)	1 (12)

* Values are the number (%). TNF = tumor necrosis factor; MTX = methotrexate.

† Mean ± SD 15.8 ± 15.6 weeks among etanercept users and 6.2 ± 8.8 weeks among infliximab users.

the known underreporting of adverse events to MedWatch (31).

Infliximab-associated lymphoma. Eight cases of lymphoma occurring after initiation of infliximab treatment were reported to the FDA between May 1999 and December 2000 (Table 3). One patient, with non-Hodgkin's lymphoma, was reported as deceased. These lymphomas occurred a median of 6 weeks (range 2–44 weeks) after the initiation of therapy with infliximab in the 7 cases for which this information was provided.

The median age of the patients with infliximab-associated lymphoma was 62 years. The majority of the infliximab-treated patients were male (62.5%), and the most common treatment indication was CD (62.5%) (Table 2). Other immunosuppressive drugs reported as

Table 3. Lymphomas occurring in patients treated with infliximab*

Patient	Age/sex	Lymphoma cell type	Weeks from first infliximab dose to lymphoma diagnosis	Vital status	Immunosuppressive drugs			EBV associated with lymphoma
					MTX	Other	CTD	
1	77/M	Burkitt's lymphoma	6	Alive	P	–	NR	NR
2	NR	Hodgkin's disease, n.o.s.	NR	Alive	Unknown	Unknown	NR	NR
3	43/F	Hodgkin's disease, nodular sclerosis subtype	44	Alive	–	–	–	NR
4	34/M	Diffuse large B cell NHL	4	Alive	–	6MP	NR	Positive
5†	70/M	Diffuse large cell NHL	6	Alive	–	–	–	NR
6‡	29/M	Hodgkin's disease, nodular sclerosis subtype	2	Alive	–	–	NR	NR
7	68/F	B cell NHL, n.o.s.	24	Alive	C	AZA	–	NR
8	62/M	Large B cell NHL	36	Dead	Unknown	AZA	NR	NR

* Table does not include 1 patient who received infliximab therapy for 2 years prior to being switched to etanercept (patient 12, Table 1). This patient developed lymphoma 3 weeks after beginning etanercept therapy. 6MP = 6-mercaptopurine (see Table 1 for other definitions).

† Patient displayed significant reduction in axillary lymphadenopathy after discontinuation of infliximab, in the absence of standard antilymphoma chemotherapy.

‡ Patient has been reported previously (39).

having been used by these patients included MTX (2 of 8), AZA (2 of 8), and 6-mercaptopurine (1 of 8). Five of the 8 infliximab-associated lymphoproliferative disorders were non-Hodgkin's lymphoma, and 3 were Hodgkin's disease.

The number of infliximab users in the US is estimated by the manufacturer to be ~121,000 as of March 2001. Thus, an estimate of the reported occurrence of lymphoma in infliximab users is 8/121,000, or ~6.6 cases per 100,000 treated persons. As noted above, this estimate is likely to be an underestimate based on underreporting. The uncertainty that underlies the estimates for lymphoma among etanercept users and infliximab users is sufficiently great to prohibit direct comparison of the "rate" of lymphoma associated with the 2 different drugs.

It should be noted that 1 subject in this case series (patient 12 in Table 1) was treated with both agents. He received infliximab for 2 years and then switched to etanercept. Lymphadenopathy was noted after the seventh dose of etanercept. He is tabulated formally among the etanercept users since that was the agent he was taking when the lymphoma developed.

Additional information reported. Additional information was provided in response to our letter, for 11 of 18 etanercept cases (61%) and 5 of 8 infliximab cases (62.5%). Information on EBV status was received for only 2 subjects: 1 etanercept-treated patient was reported as EBV negative, and 1 infliximab-treated patient was reported to be EBV positive.

In 1 case (patient 17 in Table 1), a thymoma was

observed to shrink and necrose after the discontinuation of etanercept. In a second patient (patient 5 in Table 3), a significant reduction in axillary lymphadenopathy was reported after discontinuation of infliximab. Both "responses" occurred in the absence of standard antilymphoma chemotherapy. No other information was received from physicians regarding whether attempts were made routinely or systematically to determine if these lymphoproliferative disorders regressed after anti-TNF therapy was discontinued.

Among the patients treated with etanercept for refractory RA, 2 were reported to have had Sjögren's syndrome, and 1 each had dermatomyositis and systemic lupus erythematosus. None of the patients treated with infliximab had a reported history of a connective tissue disease besides RA. The father of 1 etanercept-treated patient was reported to have had non-Hodgkin's lymphoma. In none of the remaining 25 cases was a significant family history of cancer or lymphoproliferative neoplasia reported, although in most instances, information on family history of malignancy was simply not included.

Slides or pathology samples were available from 1 etanercept-treated and 2 infliximab-treated patients. In all 3 cases, the pathologic diagnosis rendered by the referring pathologist was confirmed by review in the National Cancer Institute's Laboratory of Pathology. The lack of pathology specimens from 23 of the 26 patients precluded a more systematic analysis of those data.

DISCUSSION

The FDA's passive postmarket adverse event reporting system (MedWatch) received 18 reports of lymphoma subsequent to the initiation of etanercept therapy and 8 reports of lymphoma subsequent to the initiation of infliximab therapy during the 2½ years since these novel biologic agents were licensed for clinical use in the US. One patient had been exposed to both medications. An estimate of the reporting rate for lymphoma after etanercept therapy, based on the manufacturer's estimates of the number of patients using this drug, is 19/100,000. The reporting rate for lymphoma in infliximab-treated patients is 6.6/100,000. Incomplete ascertainment of cases, and the lack of accurate information regarding the size of the populations exposed to these 2 medications, prevented our calculating reliable lymphoma rates. Thus, we could not determine whether the occurrence of lymphoma in these subjects was greater than that which would have been expected based on general population incidence rates or among untreated patients with RA or CD. The age-adjusted incidence of lymphoma in the US from 1992 to 1998 was 18.3/100,000 (15.7/100,000 for non-Hodgkin's lymphoma and 2.6/100,000 for Hodgkin's lymphoma) (32,33).

Currently available data do not permit us to draw definitive conclusions regarding whether these TNF antagonists were the proximate cause of the reported lymphomas, whether these neoplasms developed as part of the natural history of the underlying medical conditions, or whether they occurred as a complication related to other immunosuppressive medications to which these patients were exposed. Disentangling the relative contributions of innate lymphoma susceptibility, other immunosuppressive medications, and the anti-TNF agents to the development of lymphomas is impossible with the present data. A further complication is the suggestion that lymphoma represents a complication that is specific to the subset of RA patients who have severe disease (12). Clearly, patients who are currently prescribed etanercept or infliximab are those whose RA has proven refractory to standard therapy. Thus, it is conceivable that the apparent lymphoma cluster observed in this setting reflects the selection of a subpopulation of RA patients with particularly aggressive disease, rather than being related to the treatment received by such patients.

TNF is a proinflammatory cytokine that has been implicated in the etiology of both RA (34,35) and CD (36). The activities of TNF are pleiotropic and its role in the immune response incompletely understood. It is biologically plausible that TNF antagonists, which are

novel immunomodulatory agents, might produce significant adverse effects, including an increased risk of malignancy. It was recently reported that active tuberculosis and other serious infections were observed soon after the initiation of treatment with infliximab, suggesting immunomodulation as a potential contributor to risk of infection or reactivation of the disease (37).

Both RA and CD are recognized as diseases that are linked to an altered or dysfunctional immune response. Consequently, the issue of increased risk for lymphoproliferative disease has been of interest in both disorders (2,7,13,14). Furthermore, because both RA and CD are treated with immunosuppressive medications, the role of concomitant or prior immunosuppressive therapy has added a layer of complexity in the effort to clarify the causal pathway by which these malignancies arise (17).

There are numerous case series reports of the occurrence of lymphomas, especially non-Hodgkin's lymphomas, in RA patients treated with the folic acid analog MTX (5,18–21). The role of EBV infection in these patients is also of interest (7,20,21,28). In considering whether MTX played an etiologic role in RA-associated lymphoma, Georgescu and Paget (28) noted that the strongest evidence came from well-documented cases in which the lymphoma regressed after the withdrawal of MTX treatment (22). The fact that a majority of the RA patients in the present series had either prior or concurrent exposure to MTX raises the possibility that the anti-TNF agents might further compromise immune function in patients with latent EBV infection, thereby facilitating the evolution of a lymphoproliferative disorder. We cannot discern from available data whether this might have occurred in the absence of MTX exposure.

An excess of lymphomas in patients with CD has also been noted in some studies (13,14), but not all (15). As in RA, it has been suggested that the lymphoma excess in CD is, at least partially, independent of the immunosuppressive therapy used in the disorder (16). AZA is the most commonly prescribed immunosuppressive therapy for CD, and this agent has been implicated in the pathogenesis of lymphoma (17,24). Only 3 patients in this series are known to have been exposed to AZA or its metabolite, 6-mercaptopurine.

In general, the lymphomas that occur in the setting of impaired immune function are B cell, non-Hodgkin's lymphomas, most often large cell lymphomas (3,29), and the same is true in the current series, in which 21 of 26 cases were non-Hodgkin's lymphoma. We believe, however, that it is appropriate to include the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.